2-fluoro-araatp has been researched along with fludarabine in 15 studies
| Studies (2-fluoro-araatp) | Trials (2-fluoro-araatp) | Recent Studies (post-2010) (2-fluoro-araatp) | Studies (fludarabine) | Trials (fludarabine) | Recent Studies (post-2010) (fludarabine) |
|---|---|---|---|---|---|
| 22 | 2 | 2 | 3,452 | 812 | 1,415 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (26.67) | 18.7374 |
| 1990's | 6 (40.00) | 18.2507 |
| 2000's | 4 (26.67) | 29.6817 |
| 2010's | 1 (6.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gandhi, V; Plunkett, W | 2 |
| Gandhi, V; Keating, M; Kemena, A; Plunkett, W; Shewach, DS | 1 |
| Chubb, S; Huang, P; Plunkett, W | 1 |
| Danhauser, L; Gandhi, V; Iacoboni, S; Keating, M; Liliemark, J; Plunkett, W | 1 |
| Avramis, VI; Plunkett, W | 1 |
| Bennett, LL; Brockman, RW; Cheng, YC; Derse, D; Tseng, WC | 1 |
| Gandhi, V; Keating, MJ; Plunkett, W; Robertson, LE | 1 |
| Gandhi, V; Keating, MJ; Kemena, A; Plunkett, W | 1 |
| Du, M; Estey, E; Gandhi, V; Keating, MJ; Plunkett, W | 1 |
| Plunkett, W; Sampath, D | 1 |
| Dai, Y; Decker, R; Dent, P; Grant, S; Harvey, S; Kramer, L; Schaefer, G; Tang, L | 1 |
| Keating, MJ; Nowak, BJ; Plunkett, W; Yamauchi, T | 1 |
| Kawai, Y; Takagi, K; Ueda, T; Yamauchi, T | 1 |
| Aweeka, F; Chan, D; Cowan, MJ; Dvorak, CC; Huang, L; Ivaturi, V; Jennissen, C; Liu, T; Long-Boyle, J; Orchard, PJ; Pai, SY; Stricherz, M; Tolar, J; Wahlstrom, J | 1 |
2 trial(s) available for 2-fluoro-araatp and fludarabine
| Article | Year |
|---|---|
Cellular pharmacology of fludarabine triphosphate in chronic lymphocytic leukemia cells during fludarabine therapy.
Topics: Adult; Aged; Antineoplastic Agents; Arabinonucleotides; Female; Humans; In Vitro Techniques; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Male; Middle Aged; Vidarabine | 1993 |
Pharmacokinetics and Model-Based Dosing to Optimize Fludarabine Therapy in Pediatric Hematopoietic Cell Transplant Recipients.
Topics: Adolescent; Arabinonucleotides; Biomarkers, Pharmacological; Child; Child, Preschool; Disease-Free Survival; Hematopoietic Stem Cell Transplantation; Humans; Infant; Metabolic Clearance Rate; Patient-Specific Modeling; Precision Medicine; Prospective Studies; Transplant Recipients; Transplantation Conditioning; Vidarabine | 2017 |
13 other study(ies) available for 2-fluoro-araatp and fludarabine
| Article | Year |
|---|---|
Cell cycle-specific metabolism of arabinosyl nucleosides in K562 human leukemia cells.
Topics: Antineoplastic Agents; Arabinofuranosylcytosine Triphosphate; Arabinonucleotides; Cell Cycle; Cytarabine; Deoxycytidine Kinase; Drug Synergism; G1 Phase; G2 Phase; Humans; Intracellular Fluid; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Metaphase; Nucleotides; S Phase; Sensitivity and Specificity; Tumor Cells, Cultured; Vidarabine | 1992 |
Inhibition of fludarabine metabolism by arabinosylcytosine during therapy.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleotides; Cytarabine; Deoxycytidine Kinase; Dose-Response Relationship, Drug; Drug Interactions; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Phosphorylation; Time Factors; Vidarabine | 1992 |
Termination of DNA synthesis by 9-beta-D-arabinofuranosyl-2-fluoroadenine. A mechanism for cytotoxicity.
Topics: Aphidicolin; Arabinonucleotides; Cell Line; Cell Survival; Clone Cells; Diterpenes; DNA Replication; DNA-Directed DNA Polymerase; Guanosine Monophosphate; Humans; Kinetics; Nucleic Acid Synthesis Inhibitors; Vidarabine; Vidarabine Phosphate | 1990 |
Modulation of arabinosylnucleoside metabolism by arabinosylnucleotides in human leukemia cells.
Topics: Arabinofuranosylcytosine Triphosphate; Arabinonucleotides; Cytarabine; Humans; Leukemia; Phosphorylation; Tumor Cells, Cultured; Vidarabine | 1988 |
Comparison between the plasma and intracellular pharmacology of 1-beta-D-arabinofuranosylcytosine and 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate in patients with relapsed leukemia.
Topics: Adult; Arabinofuranosylcytosine Triphosphate; Arabinonucleotides; Cytarabine; DNA Replication; Drug Evaluation; Female; Half-Life; Humans; Leukemia; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Vidarabine | 1987 |
2-fluoro-ATP: a toxic metabolite of 9-beta-D-arabinosyl-2-fluoroadenine.
Topics: Adenine; Adenosine Triphosphate; Animals; Arabinonucleotides; Cell Line; Chromatography, High Pressure Liquid; Leukemia P388; Leukemia, Experimental; Mice; Vidarabine | 1983 |
In vitro biological activity of 9-beta-D-arabinofuranosyl-2-fluoroadenine and the biochemical actions of its triphosphate on DNA polymerases and ribonucleotide reductase from HeLa cells.
Topics: Antiviral Agents; Arabinonucleotides; Binding, Competitive; Cell Survival; Deoxycytidine Kinase; HeLa Cells; Humans; Kinetics; Nucleic Acid Synthesis Inhibitors; Phosphorylation; Ribonucleotide Reductases; Vidarabine | 1982 |
Combination of fludarabine and arabinosylcytosine for treatment of chronic lymphocytic leukemia: clinical efficacy and modulation of arabinosylcytosine pharmacology.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arabinofuranosylcytosine Triphosphate; Arabinonucleotides; Cytarabine; Drug Administration Schedule; Drug Synergism; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Survival Analysis; Treatment Outcome; Vidarabine | 1994 |
Minimum dose of fludarabine for the maximal modulation of 1-beta-D-arabinofuranosylcytosine triphosphate in human leukemia blasts during therapy.
Topics: Acute Disease; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Arabinofuranosylcytosine Triphosphate; Arabinonucleotides; Cytarabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Leukemia, Myeloid; Male; Middle Aged; Neoplastic Stem Cells; Phosphorylation; Time Factors; Vidarabine | 1997 |
The role of c-Jun kinase in the apoptotic response to nucleoside analogue-induced DNA damage.
Topics: Antineoplastic Agents; Apoptosis; Arabinonucleotides; Caspases; DNA; DNA Damage; Enzyme Activation; Humans; Leukemia, Myeloid; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 8; Mitogen-Activated Protein Kinases; S Phase; Tumor Cells, Cultured; U937 Cells; Vidarabine; Vidarabine Phosphate | 2000 |
Interactions between 2-fluoroadenine 9-beta-D-arabinofuranoside and the kinase inhibitor UCN-01 in human leukemia and lymphoma cells.
Topics: Alkaloids; Antineoplastic Agents; Apoptosis; Arabinonucleotides; Blotting, Western; Drug Interactions; Drug Synergism; Enzyme Inhibitors; HL-60 Cells; Humans; Leukemia; Lymphoma; Phosphorylation; Protein Kinase C; Proto-Oncogene Proteins c-bcl-2; Staurosporine; U937 Cells; Vidarabine | 2001 |
DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine.
Topics: Adenine Nucleotides; Antineoplastic Agents; Apoptosis; Arabinonucleosides; Arabinonucleotides; Clofarabine; Cyclophosphamide; DNA; DNA Repair; Dose-Response Relationship, Drug; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Nucleosides; Time Factors; Vidarabine | 2001 |
Inhibition of repair of carboplatin-induced DNA damage by 9-beta-D-arabinofuranosyl-2-fluoroadenine in quiescent human lymphocytes.
Topics: Antineoplastic Agents; Apoptosis; Arabinonucleotides; Carboplatin; Cell Proliferation; DNA Damage; DNA Repair; Drug Interactions; Humans; Lymphocytes; Tumor Cells, Cultured; Vidarabine | 2004 |